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Simple Summary: Incidence of colorectal cancer (CRC) has been rising in Brazil. To date, no
reliable biomarker has been described in CRC for diagnosis and prognosis. Modifications in the
N-glycosylation profile are usually associated with many cancers, as CRC. In turn, mass spectrometry
(MS)-based methods are the most accurate technology in quantification of N-glycans. Therefore, we
described a unique pattern of compositions altered in serum and tissues of stages II and III colon
cancer patients, identified by MALDI-TOF/MS and LC-MS technology. N-glycans were mostly
found decreased in serum whilst oligomannosidic, hypogalactosylated, and tetra-antennary forms
were overexpressed in tumor tissues. Total N-glycome in serum of cancer patients was different
from the profile found in serum of healthy individuals. Strikingly, no correlation between tissue
N-glycosylation profile and serum profile was observed in cancer patients, posing the question where
these compositions are originated from.
Abstract: Colorectal cancer (CRC) ranks second as the leading cause of cancer-related deaths world-
wide. N-glycosylation is one of the most common posttranslational protein modifications. Therefore,
we studied the total serum N-glycome (TSNG) of 13 colon cancer patients compared to healthy
controls using MALDI-TOF/MS and LC-MS. N-glycosylation of cancer tumor samples from the
same cohort were further quantified using a similar methodology. In total, 23 N-glycan compositions
were down-regulated in the serum of colon cancer patients, mostly galactosylated forms whilst the
mannose-rich HexNAc2Hex7, the fucosylated bi-antennary glycan HexNAc4Hex5Fuc1NeuAc2, and
the tetra-antennary HexNAc6Hex7NeuAc3 were up-regulated in serum. Hierarchical clustering
analysis of TSNG correctly singled out 85% of the patients from controls. Albeit heterogenous, N-
glycosylation of tumor samples showed overrepresented oligomannosidic, bi-antennary hypogalac-
tosylated, and branched compositions related to normal colonic tissue, in both MALDI-TOF/MS
and LC-MS analysis. Moreover, compositions found upregulated in tumor tissue were mostly uncor-
related to compositions in serum of cancer patients. Mass spectrometry-based N-glycan profiling
in serum shows potential in the discrimination of patients from healthy controls. However, the
compositions profile in serum showed no parallel with N-glycans in tumor microenvironment, which
suggests a different origin of compositions found in serum of cancer patients.
Keywords: colorectal cancer; LC/MS; MALDI-TOF/MS; N-glycosylation; mass spectrometry
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1. Introduction
Colorectal cancer (CRC) is the third most common cancer worldwide, with an annual
incidence of approximately 1.8 million new cases, of which 900,000 are expected to die
from this malignancy [1]. While its incidence is declining in developed countries, a steady
increase has been observed in Brazil in recent years [2].
Survival is closely related to clinical stage as fewer than 10% patients with metastatic
disease will survive longer than 5 years. On the other hand, patients with early diagnosis
show a disease-free survival rate close to 90% [3]. Therefore, early detection of CRC is key.
Currently, colonoscopy is the gold standard for diagnostic purposes in CRC, and albeit
highly accurate, this is an invasive method, not exempt from complications. In turn, many
biomarkers currently in use, mostly carbohydrate antigens such as CEA and CA 19-9, show
low sensitivity and specificity in CRC early detection [4].
After surgical resection, surveillance is recommended for CRC patients to early detec-
tion of recurrent disease. Even though many patients will receive adjuvant chemotherapy,
some of them will not benefit from treatment, eventually developing metastasis. Therefore,
there is a pressing need to discover new and more reliable biomarkers for early detection
and prognosis in CRC, maybe present in human tissues or in biofluids [5,6].
Selective pressure within the tumor microenvironment leads to significant modi-
fications of several clones, with better adapted tumor cells overgrowing. Progressive
mutations in oncogenes and tumor suppressor genes enable malignant cells to cope with
these environment changes [7].
However, more plastic phenotype expressions, as epigenetic and posttranslational
events, are frequently involved in tumor development. In fact, cell-cell, cell-extracellular
matrix, and complex interplay between host immune system and tumor cells are all
dynamic processes, highly mediated by glycocalyx interaction [8].
Glycosylation is one of the most common posttranslational modifications (PTM) in
proteins where oligosaccharides are covalently attached to nascent polypeptide chains
in the endoplasmic reticulum. These carbohydrates are also involved in proper protein
folding, final intracellular location, or secretion as extracellular vesicles, turnover, and pro-
teolysis. Approximately 60% of all human proteins are glycosylated, with N-glycosylation
occurring when a glycan is attached to asparagine (Asn) in the motif Asn-X-Ser/Thr, where
X is not a proline residue [9].
Unlike DNA or proteins, glycans are formed with no previous template, which
increases the complexity and possibility of variations in compositions and structures.
Therefore, high-throughput analytic technologies, such as capillary electrophoresis, high
and ultra-performance liquid chromatography, and modern mass spectrometry (MS), are
needed to perform in-depth analysis of micro-structural composition and quantification of
these highly variable structures (e.g., glycoconjugates) that are usually present in minute
amounts into biologic materials [10,11].
Aberrant glycosylation has been acknowledged as a hallmark of cancer as a result of
alterations in machinery of tumor cells, albeit it is not clear this phenotypical modification
is cause of consequence of malignant transformation [7,12,13]. Over the last 10 years,
many studies have focused on the role of N-glycosylation in CRC. Albeit heterogeneous,
colorectal tumors revealed a distinct pattern including increase of mannose rich, acidic N-
glycans, core-fucosylated bi-antennary, multi-antennary sialylated and decrease of bisected
forms in microenvironment of tumor samples [14–20].
Recently, mass spectrometry imaging (MSI)-based study in stage II CRC has revealed
spatial distribution of N-glycans in the tumor microenvironment with increase of mannose
rich and sialylation levels in stroma, spreading into the tumor invasive front [21].
Since tumors may shed glycoproteins into serum, the analysis of N-glycome in blood
samples from cancer patients may serve as a read out of the tumor microenvironment,
therefore, providing a reliable source of cancer biomarkers [22].
More importantly, the human total serum N-glycome (TSNG) has comprehensively
been described and, albeit variations amongst normal individuals, it is believed that many
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pathologic states including inflammation and cancer promote significant modifications on
glycoproteins, easily identifiable from healthy individuals [23–25].
In this setting, by using fluorophore-assisted carbohydrate electrophoresis (FACE),
Zhao et al. were able to find globally decreased levels of core-fucosylated N-glycans in
serum of colorectal cancer patients with high predictive value in single out cases from
adenoma patients and healthy individuals [26].
Relatedly, Doherty et al. analyzed by Ultra-High Performance Liquid Chromatography
(UHPLC) technology the TSNG of a large cohort of CRC patients and controls. The
authors observed overall decrease in core-fucosylated neutral biantennary N-glycans,
whilst chromatograms peaks of multi-antennae sialylated glycoforms were found increased
in serum of CRC cases [27].
The present work also deals with similar CRC events as mentioned on the studies
above. Nevertheless, previous MS-based studies for biomarker discovery have addressed
the N-glycome in serum or the N-glycome in tissues of CRC patients separately, as one
assumes that compositions found in blood stream may reflect glycosylation present in the
tumor microenvironment. In this study we analyzed, both serum and tissue N-glycome
of CRC patients, by two MS-based technologies, MALDI-TOF/MS and LC-MS, which
revealed a special serum pattern compared to healthy individuals. More importantly,
N-glycome in serum of CRC patients was highly different from compositions observed in
tumor tissues.
2. Materials and Methods
2.1. Chemical and Reagents
Guanidine chloride, glacial acetic acid, formic acid (FA), and chloroform (Bio Clinical Lab,
Phillipsburg, NJ, USA). Dimethyl sulfoxide (DMSO), sodium hydroxide beads, iodomethane,
methyl-deuterium iodide, Trypsin (TPCK-treated from bovine pancreas) were purchased
from Sigma-Aldrich (St. Louis, MO, USA). N-Glycanase (PNGase F) was purchased from
Prozyme (Hayward, CA, USA). Meanwhile, MALDI-TOF/MS calibrant mixture (calibrant
Standard II) 2,5-Dihydroxybenzoic acid (2,5-DHB) was purchased from Bruker Daltonics
(Bremen, Germany). LC-MS grade water, acetonitrile, and methanol were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Sep-pak C-18 E 3.0 cc cartridges Strata X SPE were
purchased from Phenomenex (Torrance, CA, USA), while Amicon Ultra-0.5 Centrifugal Filter
Unit with Ultracel-10 membrane was from EMD Millipore (Billerica, MA, USA).
2.2. Patients and Controls
We evaluated 15 patients with sporadic microsatellite stable (MSS) colon cancer in
stage II or III disease, who underwent surgery at the University Hospital of Brasilia from
October 2017 to June 2018.
Initially, sporadic cancer was defined as cases that not fulfilled Amsterdam II criteria.
Synchronous or metachronous tumors, tumors from polyposis adenomatous familial
phenotype, and tumors in the inflammatory bowel disease (IBD) setting were not included.
To rule out Lynch syndrome and other CRC hereditary syndromes, all enrolled patients
underwent 37-panel genetic testing to detect germinative pathogenic mutations (APC ATM
BARD1 BLM BRCA1 BRCA2 BRIP1 CDH1 CDK4 CDKN2A CHEK2 EGFR EPCAM FANCC
MEN1 MET MLH1 MSH2 MSH6 MUTYH NBN NF1 NF2 PALB2 PIK3CA PMS2 PTEN
RAD51C RAD51D RB1 RECQL RET STK11 TP53 WT1 POLD1 POLE).
All tumor samples demonstrated proficient DNA mismatch repair protein expression
on immunohistochemistry analysis. Each tumor sample was also tested for EGFR, NRAS,
KRAS (codons 12 and 13), and BRAF V600E hot spot mutation in exon 15.
Staging was according to the 8th edition of American Joint of Committee on Cancer [28].
For the control group, we enrolled 15 never smokers, non-diabetic, with no-inflammatory
chronic conditions, otherwise healthy individuals. They had screening colonoscopies in which
no inflammatory bowel disease (IBD), polyps, or cancer were detected.
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This study was approved by the Ethic Committee and Research of University of Brasilia,
UnB DOC 63183716.0.0000.5558/2017. Written informed consent was created in accordance
with Declaration of Helsinki and voluntarily obtained from all patients and controls.
2.3. Samples
2.3.1. Serum
Blood samples (5 mL) from each colon cancer patient were collected in the morning be-
fore the surgical procedure plus from 11 healthy controls, immediately before colonoscopy.
After centrifugation for 4 min at 13,400 rpm, serum was collected and frozen at −80 ◦C.
2.3.2. Tissue
Immediately after the resection of the surgical specimen, 6 fragments 1 × 1 cm were
collected: 2 from the proximal tumor border, 2 from the distal tumor border and, 2 fragments
from mucosa and submucosa of macroscopically normal colonic tissue, located 10 cm distant
from the tumor border. All 6 fragments were frozen at −80 ◦C.
All tumor samples demonstrated proficient DNA mismatch repair protein expression
(MSS tumors), identified by immunohistochemistry analysis. Each tumor sample was also
tested for EGFR, NRAS, KRAS (codons 12 and 13), and BRAF V600E mutations. Only distal
fragments were processed for tissue extraction. Proximal samples were stored as repository
for further analysis when deemed necessary.
2.4. Protein Extraction from Tissue Samples
Tissues were pulverized on liquid nitrogen by using a mortar and were stored at
−80 ◦C. For protein extractions, 60 mg of powdered tissue were dissolved in 500 µL of a
50% acetonitrile (ACN) solution in water, vortexed for 1 min, extracted in a bath sonicator
for 45 min at room temperature, and subsequently centrifuged at 14,000 rpm for 45 min.
The upper liquid phase was collected and freeze dried for posterior glycoprotein extraction.
2.5. N-Glycan Isolation and Derivatization
Isolation of N-linked oligosaccharides was carried out by using the method described
by Morelle and Michalsky [29] with some minor modifications. Briefly, 40 µL of serum or all
powdered tissue extract were submitted to protein reduction and alkylation. For reduction,
it was used 9.6 µL of dithiothreitol (DTT) 500 mM and for alkylation 9.2 µL iodoacetoamide
(IAA) 3M, in 200 µL of a buffer solution (pH 8.4). Polypeptides were filtered through size-
exclusion Centricon, with 10 kDa cut-off and posteriorly submitted to trypsin proteolysis.
Trypsin digestion was carried out by adding 14 µL of a trypsin solution (5 µg/µL) to
reduced and alkylated glycoproteins for 24 h, at 37 ◦C. N-glycans were released from the
digested glycoprotein after incubation with 3 µL of PNGAse F solution (1 µg/µL) at 37 ◦C
for 17 h, and these were subsequently purified by sequential elution in 5% acetic acid
through a Sep-Pak C18 column. Sep-Pak C18 columns were sequentially conditioned with
5 mL of methanol and 10 mL of 5% acid acetic solution. Samples containing free N-glycans
and peptides were resuspended in 200 µL of 5% acetic acid and added to the previously
conditioned Sep-Pak columns. Sequential elutions were carried out by adding 3 mL of 5%
acetic acid and 3 mL of 5% acetic acid with 80% acetonitrile. Free N-glycans were collected
after elution with 3 mL of 5% acetic acid. N-glycans isolated from colorectal cancer
tissues and serum of CRC patients were derivatized using a light isotope of iodomethane
(I-CH3) while N-glycans isolated from normal colorectal tissues and serum of control
patients were derivatized using the heavy isotope of iodomethane (deuterated, I-CD3),
under continuous N2 flushing. Derivatized N-glycans were extracted by a liquid/liquid
approach using chloroform that was repeatedly washed with Milli-Q water and dried by a
stream of nitrogen. Samples were dissolved in acetonitrile and subsequently purified using
a Sep-Pak C18: derivatized N-glycans eluted from Sep-Pack column in 80% acetonitrile
after performing washes with water and 10% acetonitrile solution, consecutively. Purified
derivatized N-glycans were collected and freeze dried.
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2.6. Determination of N-Glycan Profile from Blood Samples
The profile of N-glycans from blood samples was performed like described before [30],
with minor modifications. Briefly, the same volume of the blood plasma obtained from
control patients (11 samples) were joined in a solution denominated control pool. N-glycans
isolated from each individual (13 colon cancer and 11 control patients) were derivatized
with the light isotope of iodomethane (I-CH3) while 24 samples corresponding to N-
glycans isolated from control pool were derivatized using a heavy isotope of iodomethane
(I-CD3). After purification of the derivatized N-glycans, each of the permethylated samples
were mixed with another sample corresponding to a control pool, in a proportion of 1:1.
Samples were freeze dried and stored at −80 ◦C before analysis. All 24 samples, containing
methylated and deuterated glycans were analyzed by MALDI-TOF/MS and LC-MS. The
ratio between signals produced in mass spectra or TIC for each methylated glycan was
calculated by using the heavy isotope signal corresponding to the same structure, when
present, as reference (I-CH3/I-CD3 signals). Choice of the heavy reference for structures
without corresponding deuterated signal was based on both structural similarity and signal
intensity (Supplementary Material 1). Additionally, the values of the ratios obtained for
each N-glycan structure were normalized by the area ratio of the bi-antennary glycan
HexNAc4Hex5NeuAc2 ([M + Na]+ = 2792.4 Da), and this glycan (52 in our numbering
system) was excluded from further analyses. Normalized area ratios were standardized
and submitted to hierarchical clustering using the Ward’s distance matrix. A constellation
plot was calculated based on the dendrogram generated by the hierarchical clustering
analysis. All statistical analyses were performed using JMP v14.0.
Glycoworkbench 2.0 software was used for calculation of the N-glycan structures
(permethylated and perdeuterated).
2.7. Determination of N-Glycan Profile from Tissue Samples
Permethylated N-glycans isolated from colorectal cancer tissues (light isotopes) were
joined to deuterated N-glycans isolated from normal colorectal tissues (heavy isotopes) in a
1:1 proportion, in order to independently measure the mass spectrometry signals produced
by each structure isolated from both tissues of each patient. Samples corresponding to
each of the patients (n = 13) were analyzed by MALDI-TOF/MS and LC-MS and the ratio
between signals produced in mass spectra or TIC for each methylated glycan was calculated
by using the heavy isotope signal of the same structure as reference (I-CH3/I-CD3 signals).
For MALDI-TOF/MS data only ions with areas ≥5% of the base peak were considered for
qualitative and quantitative analysis. Similarly, only ions with signal/noise (S/N) ratio
≥1000 were used to evaluate altered ions in the LC-MS methodology. Glycoworkbench
2.0 software and previous published N-glycans structures described in normal colorectal,
colorectal cancer tissues, and serum human N-glycome were used as reference for structural
identification [31–34].
2.8. Mass Spectrometry Acquisitions and Analysis
MALDI-TOF/MS and LC-MS/MS acquisition were performed exactly according to
Barbosa et al. [30].
2.9. MALDI-TOF/MS
Each sample was dissolved in 30 µL of acetonitrile, mixed with 2,5-dihidroxybenzoic
acid (DHB) ionization matrix (10 mg/mL in acetone containing sodium acetate 3 mM)
in a proportion of 1:3, spotted on a MALDI-target plate and dried at room temperature.
An UltraFlex III extreme mass spectrometer (Bruker Daltonics) operating in the positive
mode and controlled by FlexControl 4.0 software was used for acquisitions. The mass
range analyzed was between m/z 1500–4500. Before acquisitions, the mass spectrometer
was calibrated by using Peptide Calibration Standard II (Bruker Daltonics). Mass spectra
analysis as well as calculation of the areas under peaks of interest were performed using
FlexAnalysis 3.4 software. Spectra were re-calibrated using the ions at m/z 1835.9, 2040.0,
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2431.2, 2792.4, 2910.2, 3602.8, 4413.2, and 4597.3 as internal standards. Mass lists were
generated applying Snap Peak Detection Algorithm, TopHat Baseline Subtraction, and
Signal to Noise Threshold equal to 6. Values obtained were exported to Microsoft Excel for
further calculations and statistical analyses.
2.10. ESI-LC-MS/MS
All samples were dissolved in 40 µL of MeOH containing 10 mM sodium acetate. Mass
spectrometry acquisitions of each sample were performed by automatic injection of 6 µL
through an ekspertTMultralc 100-XL chromatography system (Eksigent, Dublin, CA, USA)
equipped with a Kinetex 2.6 µm C18 100 Å (50 × 2.1 mm) LC Column connected to a
TripleTOF 5600+ mass spectrometer (Sciex, Concord, ON, Canada) housing a DuoSpray Ion
Source. The solvents used for reversed phase chromatography were Milli-Q H2O containing
formic acid 0.1% (solvent A) and MeOH containing formic acid 0.1% (solvent B). Samples
eluted across a linear gradient of solvent B ranging from 30 to 95% in 10 min with a flow rate
of 0.4 mL/min and at a constant temperature of 40 ◦C. Ion source operated in the positive
mode at a temperature of 650.0 ◦C. Mass spectrometer worked in the high-resolution mode
with curtain gas equal 15 and mass rage of acquisitions between m/z 800–2000. Other
acquiring parameter: number of cycles = 2043; period cycle time = 525 ms; polarity = posi-
tive; pulser frequency = 13.569 kHz; and accumulation time = 500.00 ms. Mass spectrometer
was calibrated using APCI positive calibration solution before acquisitions until obtaining
an accuracy of ~0.2 ppm. MultiQuantTM 3.0.2 software (Sciex, Concord, ON, Canada) was
used for calculation of peak areas. LC-MS acquisitions were re-calibrated using peaks
m/z 702.86381, 838.83862, 974.81343, 1110.78824, 1246.76305, 1382.73786 resulting from
Sodium acetate aggregation as internal standards. Ions were extracted using theoretical
glycan masses ±0.005 Da. Area values were exported to Excel for further calculations and
statistical analyses.
Fragmentation spectra (MS/MS) of N-glycans were acquired in IDA (Information De-
pendent Acquisition) mode. Ions with charge state ranging from 2 to 4 were automatically
selected and fragmented using dynamic collision energy mode. MSConvert (ProteoWiz-
ard 3.0) was used for conversion of LC-MS/MS data from WIFF to mzXML format. The
fragmentation spectra were automatically annotated using GRITS Tollbox 1.2 software. The
parameters of annotation were: 5.0 ppm of accuracy MS; 500 ppm of accuracy MSn; 5.0%
of fragment intensity cut-off; perMe or perDMe derivatization type; free reducing end;
N-glycans—1190 glycans search data base; maximum of 3 cleavages; maximum of 1 cross
ring cleavages; glycosidic cleavages of B, Y, C, and Z series; cross ring cleavages of A and
X series; maximum of 4 charges as sodium adducts. The annotated spectra were exported
to Excel and printed to PDF files. Additionally, GlycoWorkbench 2.1 build 146 software
was applied to analyze and annotate some spectra whose precursor ion mass matched
accurately to N-glycans that were not annotated by the GRITS Toolbox.
3. Results
Fifteen patients previously diagnosed with sporadic colon cancer underwent surgical
procedures in the Division of Colorectal Surgery at the University Hospital of Brasilia and
were enrolled in the present study. Out of these, two patients were excluded: a 57-year-old
patient who refused to perform a genetic test for a germinative pathologic mutation and
a 37-year-old patient with a well-differentiated adenocarcinoma in transverse colon, as he
tested positive for germinative pathological mutation in MLH1 gene. The clinicodemo-
graphic characteristics of the remaining 13 patients are listed in Table 1.
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Table 1. Clinicodemographic characteristics of patients.
Patient Genre Age (years) Location Stage CEA (ng/mL) Tumor Diameter (cm) MutationalNras/Kras/Braf Status
1 M 37 TRANSVERSE II 1.48 3.70 Kras mutated
2 F 36 SIGMOID II 1.65 2.80 No
3 M 65 CECUM II 1.60 4.30 Kras mutated
4 M 55 DESCENDING III 5.30 2.60 No
5 M 60 SIGMOID II 7.70 4.80 No
6 F 56 SIGMOID III 2.10 3.70 No
7 M 67 ASCENDING III 2.30 6.00 Braf mutated
8 F 64 CECUM III 11.25 4.10 No
9 F 63 CECUM II 6.51 6.20 No
10 F 54 SIGMOID III 3.30 3.50 Braf mutated
11 F 74 SIGMOID III 6.75 1.20 No
12 M 64 CECUM III 5.20 7.20 Kras mutated
13 F 75 SIGMOID II 1.35 4.60 Kras mutated
CEA—carcinoembryonic antigen.
Blood serum and CRC tissue samples were obtained from cancer patients plus blood
serum from 11 out of 15 enrolled control individuals for the qualitative and quantitative analy-
sis of N-glycans using mass spectrometry techniques. Four individuals from the control group
had mild inflammatory findings on colonoscopy and were excluded. The clinicodemographic
characteristics of the 11 controls are listed in Supplementary Material 1 (Table S1).
No statistical difference was observed between age of colon cancer patients (mean
59.2 years-old, CI 95%, S.D. 11.9) and control group (mean 58 years-old, CI 95%, S.D, 5.8).
3.1. Patients with Colon Cancer Present Differential N-Glycans in Their Blood Serum in Relation
to Normal Individuals
N-glycans from the blood serum of thirteen (13) colon cancer patients and eleven (11)
control individuals were derivatized with iodomethane (I-CH3) and mixed, at a 1:1 (v/v) ratio,
with N-glycans derivatized with heavy iodomethane (I-CD3) obtained from a pool of blood
serum from control individuals. Samples were first analyzed by MALDI-TOF/MS in positive
mode for a preliminary evaluation of ions in the range of m/z 1500–5000. As anticipated,
MALDI-TOF/MS mass spectra of samples evidenced numerous ions compatible with N-
glycans found in human blood in permethylated and perdeuterated forms, detected mostly as
sodium adducts. The mass spectrum of the blood serum of one cancer patient is provided in
Figure 1A for illustration, along with the proposed structures for selected ions compatible with
N-glycans. To provide a more comprehensive coverage of serum N-glycans and to acquire
relevant structural data, reverse phase LC-MS experiments were performed. The total ion
chromatogram (TIC) of the MS analysis of the serum of a CRC patient and the extracted ion
chromatograms (XICs) for the methylated and deuterated forms of the biantennary N-glycan
HexNAc4Hex5NeuAc2 (Nr. 52 in Table 2), the most abundant in human serum, are shown
in Figure 1B.
MS/MS spectra were acquired for ions detected in the LC-MS/MS analyses of the
blood serum of all evaluated subjects. Ions were selected and fragmented according to
the acquisition parameters described in the Material and Methods section and correspond-
ing spectra were submitted to automated software interpretation. These data provide
further structural information for ions detected in MS mode, confirming that they in-
deed correspond to permethylated and deuterated N-glycans, besides narrowing down
to a restricted number of N-glycan structural isomers. As an illustration, the MS/MS
spectra of HexNAc4Hex5Fuc1NeuAc2 (precursor mass [M + 3Na]3+ = 1004.1560 Da) and
HexNAc2Hex7 (precursor mass [M + 2Na]2+ = 1005.4862 Da) in their permethylated forms,
are provided in Figure 2A,B. Fragmentation spectra of various other N-glycan ions detected
in the present study in permethylated and deuterated forms are provided as Supplementary
Material 2. These, along with other human plasma N-glycans obtained from specialized
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databases, were compiled in a table, which is provided in full as Supplementary Material 1
(Table S2) and in short form in the manuscript body as Table 2. Table 2 lists selected N-
glycan compositions and their proposed structures, the charge state, and molecular masses
used for the development of quantification methods, as well as the availability of structural
information from MS/MS spectra. It also introduces a glycan numbering system that will
be adopted throughout the present manuscript. Given that multiple ions did not produce
reliable MS/MS spectra due to low signal intensity, only ions for which tandem MS spectra
were obtained either for the permethylated or perdeuterated forms were considered in the
development of quantitation methods.
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tracted ion chromatograms for the N-glycan HexNAc4Hex5NeuAc2 in the permethylated form ([M 
+ Na]2+ = 1407.6859 Da) isolated from patient 7 and deuterated form ([M + Na]2+ = 1466.5531 Da) 
obtained from control pool. Masses and XICs in blue and red indicate light (methylated) and heavy 
(deuterated) derivatized N-glycans, respectively. The asterisks drawn in inset A correspond to the 
same N-glycans analyzed in inset B, although the latter in a different charge state than the former. 
Figure 1. Analysis of serum N-glycans by mass spectrometry. (A) MALDI-TOF/MS spectrum of
blood serum N-glycans of patient 7 mixed with those from the control pool in positive mode in the
range m/z 1500–5000. Ions whose masses correspond to methylated N-glycans are depicted in blue,
while those from deuterated structures are given in red. The two most intense peaks correspond to
the N-glycan HexNAc4Hex5NeuAc2 in its permethylated form ([M + Na]+ = 2792.4 Da), obtained
from patient 7, and deuterated forms ([M + Na]+ = 2910.1 Da), obtained from control pool. Proposed
structures were drawn for their corresponding N-glycan compositions and are depicted on top of
their cor esponding i . ( ) LC- S analysis showing total ion chromatogram (black line) and
extracted ion chromatograms for the - l i t e per ethylated form ([M
+ Na]2+ = 1407.6859 a) isolated fro patient 7 and deuterated form ([M + Na]2+ = 1466.5531 Da)
obtained from control pool. Masses and XICs in blue and red indicate light (methylated) and heavy
(deuterated) derivatized N-glycans, respectively. The asterisks drawn in inset A correspond to the
same N-glycans analyzed in inset B, although the latter in a different charge state than the former.
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Table 2. N-glycan number, structure, accurate mass, mass used for quantification, corresponding adduct, and the heavy reference number used for LC-MS/MS and MALDI-TOF/MS quantifica-
tion methods.






Biology 2021, 10, x FOR PEER REVIEW 10 of 28 
 
 
Table 2. N-glycan number, structure, accurate mass, mass used for quantification, corresponding adduct, and the heavy reference number used for LC-MS/MS and MALDI-TOF/MS 
quantification methods. 
Nr. Proposed Structure, Theoretical Mass, and Composition Mass Used for Quantitation Adduct Heavy Reference Structure Confirmed by MS/MS Data a 




















1005.4857 * [M + 2Na]2+ 52 6  
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157 [M + Na]+ 52 6 X
8
Biology 2021, 10, x FOR PEER REVIEW 10 of 28 
 
 
Table 2. N-glycan number, structure, accurate mass, mass used for quantification, corresponding adduct, and the heavy reference number used for LC-MS/MS and MALDI-TOF/MS 
quantification methods. 
Nr. Proposed Structure, Theoretical Mass, and Composition Mass Used for Quantitation Adduct Heavy Reference Structure Confirmed by MS/MS Data a 




















1005.4857 * [M + 2Na]2+ 52 6  
HexNAc3Hex4
1620.8090 [M + Na]+ 19 - *
10
Biology 2021, 10, x FOR PEER REVIEW 10 of 28 
 
 
Table 2. N-glycan number, structure, accurate mass, mass used for quantification, corresponding adduct, and the heavy reference number used for LC-MS/MS and MALDI-TOF/MS 
quantification methods. 
Nr. Proposed Structure, Theoretical ass, and Composition Mass Used for Quantitation Adduct Heavy Reference Structure Confirmed by MS/MS Data a 




















1005.4857 * [M + 2Na]2+ 52 6  
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1005.4857 * [M + 2Na]2+ 52 6  
HexNAc4Hex4
1865.9355 [M + Na]+ 19 19 XX
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1154.0701 [M + 2Na]2+ 19 19  
HexNAc5Hex4
1067.0255 [M + 2Na]2+ 19 - *
23






















1154.0701 [M + 2Na]2+ 19 19  
HexNAc6Hex3
1087.5388 * [M + 2Na]2+ 13 - X
25






















1154.0701 [M + 2Na]2+ 19 19  
HexN c
1107.5356 [M + 2Na]2+ 52 6 XX
26






















1154.0701 [M + 2Na]2+ 19 19  
exNAc4 c1
1125.0492 [M + 2Na]2+ 26 35 XX
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1154.0701 [M + 2Na]2+ 19 19  
HexNAc5Hex4Fuc1
1154.0701 [M + 2Na]2+ 19 19 X
31


















1293.6304 * [M + 2Na]2+ 27 -  
HexNAc3Hex5Fuc1NeuAc1
1191.5805 [M + 2Na]2+ 27 - XX
33


















1293.6304 * [M + 2Na]2+ 27 -  
HexNAc2Hex9
1209.5855 [M + 2Na]2+ 52 6 XX
36


















1293.6304 * [M + 2Na]2+ 27 -  
HexNAc5Hex4NeuAc1
1247.6123 [M + 2Na]2+ 52 - XX
40


















1293.6304 * [M + 2Na]2+ 27 -  
HexNAc3Hex6Fuc1NeuAc1
1293.6304 * [M + 2Na]2+ 27 - XX
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1314.1437 [M + 2Na]2+ 44 58  
HexNAc7Hex3Fuc1
1297.1465 [M + 2Na]2+ 75 - *
42


















1314.1437 [M + 2Na]2+ 44 58  
HexNAc2Hex10
1311.6353 [M + 2Na]2+ 52 - X
43


















1314.1437 [M + 2Na]2+ 44 58  
HexNAc7Hex4
1312.1518 [M + 2Na]2+ 72 - X
44


















1314.1437 [M + 2Na]2+ 44 58  
HexNAc4Hex5Fuc1NeuAc1
1314.1437 [M + 2Na]2+ 44 58 XX
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975.4711 [M + 3Na]3+ 72 35  
HexNAc5Hex5NeuAc1
907.4379 [M + 3Na]3+ 35 X
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975.4711 [M + 3Na]3+ 72 35  
Hex c6 ex6
936.7887 [M + 3Na]3+ 52 35 X
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975.4711 [M + 3Na]3+ 72 35  
HexNAc4Hex5NeuAc2
1407.6859 [M + 2Na]2+ 52 52 XX
55


















975.4711 [M + 3Na]3+ 72 35  
HexNAc5Hex6NeuAc1
975.4711 [M + 3Na]3+ 72 35 XX
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1033.5009 * [M + 3Na]3+ 27 -  
HexNAc6Hex5Fuc2
984.8149 [M + 3Na]3+ 27 - X
57
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994.8184 [M + 3Na]3+ 27 - X
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HexNAc4Hex5Fuc1NeuAc2
1004.1501 [M + 3Na]3+ 58 58 XX
61


















1033.5009 * [M + 3Na]3+ 27 -  
HexNAc5Hex6Fuc1NeuAc1
1033.5009 * [M + 3Na]3+ 27 - X
Biology 2021, 10, 343 15 of 30
Table 2. Cont.
























1030.2440 [M + 4Na]4+ 80 52  
HexNAc5Hex5Fuc1NeuAc2
1617.2937 [M + 2Na]2+ 27 64 X
66


















1030.2440 [M + 4Na]4+ 80 52  
HexNAc6Hex6Fu c1
1115.2096 [M + 3Na]3+ 27 - X
67


















1030.2440 [M + 4Na]4+ 80 52  
HexNAc6Hex7Fuc2
1669.8275 * [M + 2Na]2+ 27 - X
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1016.5017 [M + 2Na]2+ 13 -  
a one check indicates that permethylated structure was confirmed, double check indicates that both structures (permethylated and perdeuterated) were confirmed, while asterisk indi-
cates that only perdeuterated structure was confirmed. Legend: ∎ N-acetyl glucosamine (GlcNac),  Mannose (Man),  Galactose (Gal), ◄ Fucose (Fuc), ♦ Sialic acid (NeuAc).
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Biology 2021, 10, 343 17 of 30




Figure 2. MS/MS spectra of permethylated N-glycans obtained in a reverse-phase LC-MS/MS anal-
ysis of a colon cancer patient, (A) HexNAc4Hex5Fuc1NeuAc2 (precursor mass [M + 3Na]3+ = 
1004.1560 Da, Nr. 58 in Table 2) and (B) HexNAc2Hex7 (precursor mass [M + 2Na]2+ = 1005.4862 
Da, Nr. 17 in Table 2). Data interpretation was performed automatically by the software GRITS. 
Figure 2. MS/MS spectra of permethylated N-glycans obtained in a reverse-phase LC-MS/MS analysis of a colon cancer pa-
tient, (A) HexNAc4Hex5Fuc1NeuAc2 (precursor mass [M + 3Na]3+ = 1004.1560 Da, Nr. 58 in Table 2) and (B) HexNAc2Hex7
(precursor mass [M + 2Na]2+ = 1005.4862 Da, Nr. 17 in Table 2). Data interpretation was performed automatically by the
software GRITS.
Quantification methods for N-glycans in the serum of CRC and control patients were
developed for MALDI-TOF/MS and LC-MS/MS data. These methods are based on the
calculation of area ratios between ions from N-glycans derivatized with regular versus
deuterated iodomethane (-CH3/-CD3 ratios) using a “nearest neighbor” approach, similarly
to a recent publication [30]. After the calculation of area ratios for all N-glycan pairs for each
patient, data was further normalized using HexNAc4Hex5NeuAc2 (Nr. 52) as reference.
The quantification method developed for MALDI-TOF/MS data included twenty-nine (29)
N-glycans of various compositions (Supplementary Material 3; Supplementary Material 4,
Figure S1) and only one of them had significantly different area ratios in CRC patients in
relation to controls, as shown in Figure 3A. The N-glycan HexNAc5Hex5NeuAc1 (Nr. 49)
was upregulated in CRC patients, according to the Mann–Whitney U test with α = 0.01, as
detailed in Table 3.
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Table 3. Mann–Whitney U tests of the relative concentration of N-glycans in serum of cancer patients and controls obtained by MALDI-TOF/MS and LC-MS/MS.
Nr N-Glycan Composition Median Controls (n = 11) Median Cancer Patients (n = 13) Alteration in Cancer Patients Z Wilcoxon, 2-Sample Test, NormalApproximation, Prob>|Z|
MALDI-TOF/MS data
49 HexNAc5Hex5NeuAc1 0 0.022 ↑ −3.09 0.0020
LC-MS/MS data
8 HexNAc3Hex4 0.140 0.012 ↓ 3.13 0.0018
14 HexNAc4Hex4 0.685 0.023 ↓ 3.03 0.001
17 HexNAc2Hex7 0.000 0.026 ↑ −3.53 0.0004
22 HexNAc5Hex4 0.882 0.020 ↓ 3.77 0.0002
23 HexNAc6Hex3 0.466 0.005 ↓ 2.72 0.0065
25 HexNAc2Hex8 0.149 0.051 ↓ 2.72 0.0065
26 HexNAc4Hex4NeuAc1 1.619 0.160 ↓ 3.30 0.001
31 HeXNAc3Hex5Fuc1NeuAc1 4.228 0.021 ↓ 3.07 0.0021
33 HexNAc2Hex9 0.334 0.072 ↓ 3.01 0.0026
36 HexNAc5Hex4NeuAc1 0.838 0.035 ↓ 3.13 0.0018
40 HexNAc3Hex6Fuc1NeuAc1 0.413 0.000 ↓ 2.97 0.003
41 HexNAc7Hex3Fuc1 1.533 0.092 ↓ 3.25 0.0012
42 HexNAc2Hex10 0.147 0.008 ↓ 3.42 0.0006
43 HexNAc7Hex4 2.705 0.025 ↓ 3.36 0.0008
44 HexNAc4Hex5Fuc1NeuAc1 1.659 0.772 ↓ 3.01 0.0026
51 HexNAc6Hex6 9.144 0.842 ↓ 3.42 0.0006
55 HexNAc5Hex6NeuAc1 0.650 0.123 ↓ 2.66 0.0077
56 HexNAc6Hex5Fuc2 0.221 0.004 ↓ 3.02 0.0026
57 HexNAc6Hex6Fuc1 0.439 0.030 ↓ 2.66 0.0077
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Table 3. Cont.
Nr N-Glycan Composition Median Controls (n = 11) Median Cancer Patients (n = 13) Alteration in Cancer Patients Z Wilcoxon, 2-Sample Test, NormalApproximation, Prob>|Z|
58 HexNAc4Hex5Fuc1NeuAc2 0.315 0.987 ↑ −3.36 0.0008
61 HexNAc5Hex6Fuc1NeuAc1 0.414 0.069 ↓ 2.84 0.0045
66 HexNAc6Hex6Fuc1NeuAc1 0.633 0.050 ↓ 3.07 0.0021
79 HexNAc6Hex7NeuAc3 0.001 0.226 ↑ −3.19 0.0014
85 HexNAc7Hex8NeuAc4 1.188 0.000 ↓ 3.44 0.0006
86 HexNAc7Hex8Fuc1NeuAc4 0.920 0.019 ↓ 2.95 0.0031
87 HexNAc4Hex3Fuc2 0.379 0.006 ↓ 2.95 0.0031
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A similar relative quantification approach was developed for the LC-MS/MS data;
however, it included fifty-three (53) N-glycans of varying compositions evaluated herein
(Supplementary Material 3; Supplementary Material 4, Figure S2). Those that were sig-
nificantly altered in CRC patients in relation to control individuals are reported in Table 3
and in Figure 3B. Twenty-six (26) N-glycans of varying composition were found to be
significantly altered in the plasma of cancer patients. Among these, HexNAc5Hex4 (Nr. 22)
and HexNAc2Hex7 (Nr. 17) were the ones with the highest statistical significance in the
Mann–Whitney U test. Three N-glycans were found at a higher relative concentration
in the serum of cancer patients: the mannose-rich HexNAc2Hex7 (Nr. 17), the fucosy-
lated bi-antennary glycan HexNAc4Hex5Fuc1NeuAc2 (Nr. 58), and the tetra-antennary
HexNAc6Hex7NeuAc3 (Nr. 79).
To investigate whether the alterations in the relative abundance of serum N-glycans
of CRC patients detected in LC-MS/MS analyses can be used as a classification tool,
normalized -CH3/-CD3 area ratios of subjects (n = 24, 13 CRC patients, 11 controls) were
submitted to a hierarchical clustering algorithm using the Ward’s method. According to
the constellation plot provided in Figure 4, calculated from resulting dendrograms, two
main clusters were readily apparent: cluster one has twelve (12) members, and it holds ten
out of the eleven (10/11) control individuals as well as two out of thirteen (2/13) cancer
patients. Cluster two also has twelve (12) members and is formed by eleven out of thirteen
(11/13) colon cancer patients and one (1) control individual.
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Figure 4. Constellation plot generated for the N-glycans in the blood serum of CRC patients and
control individuals. The normalized and standardized -CH3/-CD3 ratios for fifty-three (53) N-glycans
obtained by LC-MS/MS analyses of the blood serum of CRC patients (•) and control individuals
(•) were submitted to a hierarchical clustering algorit using the Ward’s method and the resulting
dendrogram was depicted as a constellation plot. X and Y axes are dimensionless.
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3.2. N-Glycan Profiles in CRC Tissue Are Heterogeneous, However, Some Glycan Compositions
Are Consistently Altered in Patients
Colonic tumor samples were obtained and their N-glycans were extracted and quanti-
fied in relation to adjacent tissue of the same patients. A similar quantification methodology
was developed, however, this time, N-glycans from tumor tissue were derivatized with
I-CH3, while those from normal tissue were derivatized with I-CD3. This implies that the
area ratios of evaluated N-glycans show whether these are relatively increased (ratio > 1) or
decreased (ratio < 1) in tumor tissues in relation to normal tissue samples. Mass spectromet-
ric analyses of N-glycans in tissue extracts indicate that the CRC tumor microenvironment
is highly heterogeneous. The MALDI-TOF/MS mass spectra of patients were highly vari-
able in terms of the quality and quantity of N-glycan ions (Supplementary Material 4,
Figures S3–S15). Thus, given such high variance, only ions with areas ≥5% of the base
peak were considered for the development of quantitative methods for MALDI-TOF/MS
data. Similarly, only ions with S/N ratio ≥1000 were considered for quantitation in the
LC-MS/MS methodology. To evaluate N-glycans that were consistently altered in samples,
a binomial test was applied and those compositions presenting statistical significance are
listed in Table 4. The (-CH3/-CD3) ratios were calculated and were used to build box
plots (Figure 5).
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Figure 5. Box plots showing up- and down-regulated N-glycans isolated from tumor and normal colonic tissues of colon 
cancer patients analyzed by MALDI-TOF/MS (blue boxes) and LC-MS/MS (red boxes). The lower and upper whiskers 
represent the 5th and 95th percentile, respectively, while the median is represented as a straight line, the mean by an open 
box (⎕), and data outliers are represented by the X symbol. 
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Thirteen (13) ions matching N-glycans were consistently detected in the MALDI-
TOF/MS spectra of the tissue extract. Out of these, two (2) were increased in relation to
normal tissues: the oligomannosidic structures HexNac2Hex5 (Nr. 6) and HexNac2Hex6
(Nr. 10) (Figure 5). A full list of all detected ions and their area ratios is available as
Supplementary Material 3 and Supplementary Material 4 (Figure S16).
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Table 4. Relative concentration of N-glycans in samples of tumor and normal tissues from all cancer patients obtained by MALDI-TOF/MS and LC-MS/MS.
Patient Nr.
Nr. N-Glycan Composition 1 2 3 4 5 6 7 8 9 10 11 12 13 Median n/Total * BinomialProbability
MALDI-TOF/MS data (area ratio)
6 HexNac2Hex5 29.41 62.5 - 6.88 15.33 - 7.48 20.8 0.2 3.09 14.63 - 27.09 14.98 9/10 0.0010
10 HexNac2Hex6 42.63 7.25 - 8.71 - - 21.94 4 0.06 - 7.48 - 23.4 8.10 7/8 0.0020
LC-MS/MS data (area ratio)
17 HexNAc2Hex7 - - - 0.02 0.03 0.00 0.03 0.02 0.01 0.11 0.01 - - 0.02 8/8 0.0000
22 HexNAc5Hex4 167.48 53.17 31.47 38.23 84.42 - 7.42 110.19 1.44 4.61 6.39 - 136.41 38.23 11/11 0.0000
26 HexNAc4Hex4NeuAc1 40.70 31.47 11.41 10.34 5.26 - 1.64 24.58 - - 3.43 - 26.69 11.41 9/9 0.0000
28 HexNAc5Hex4Fuc1 51.49 17.16 46.90 - 4.20 - - 43.48 0.79 1.84 5.27 - 19.55 17.16 8/9 0.0020
33 HexNAc2Hex9 92.23 116.52 86.94 65.26 5.54 - 4.45 32.67 0.52 - 16.76 - 123.43 48.96 9/10 0.0010
36 HexNAc5Hex4NeuAc1 140.70 113.15 59.98 142.75 17.23 0.06 1.98 35.80 0.78 1.70 56.29 - 587.41 46.05 10/12 0.0032
41 HexNAc7Hex3Fuc1 20.10 26.13 21.01 10.27 27.09 - - 20.10 - - 4.52 - 59.21 20.55 8/8 0.0000
43 HexNAc7Hex4 26.12 10.94 25.56 6.74 - 0.01 1.34 7.67 0.40 1.06 1.91 - 14.29 6.74 9/11 0.0059
57 HexNAc6Hex6Fuc1 - 12.13 43.48 12.63 6.20 2.52 1.76 7.29 0.97 2.32 4.52 1.76 26.01 5.36 11/12 0.0002
64 HexNAc5Hex5Fuc1NeuAc2 7.49 24.86 6.61 14.67 - 0.62 - - 0.45 2.54 11.36 - 19.28 7.49 7/9 0.0195
67 HexNAc6Hex7Fuc2 9.62 7.77 5.74 23.82 16.50 - - 13.98 - - - - 5.50 9.62 7/7 0.0000
* n/total: n increased samples/total of samples.
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Twenty-four (24) N-glycans presented consistent ion signals in LC-MS/MS analyses of
tissue samples and were subjected to further evaluation (Supplementary Material 3; Sup-
plementary Material 4, Figure S17). One N-glycan composition was decreased in cancer
tissues, HexNAc2Hex7 (Nr. 17), with median -CH3/-CD3 ratio equivalent to 2.0 × 10−2.
Ten other N-glycan compositions were increased. Out of these, one was an oligoman-
nosidic structure, HexNAc2Hex9 (Nr. 33), with a median -CH3/-CD3 ratio of ~49 units,
being thus highly discriminative in the CRC tumor tissues evaluated herein. (Figure 5).
Still other hypogalactosylated and hyposialylated complex glycans were more abundant
in tumoral tissue, like N-glycans HexNAc5Hex4 (Nr. 22), HexNAc4Hex4NeuAc1 (Nr. 26),
HexNAc5Hex4NeuAc1 (Nr. 36), and HexNAc5Hex5Fuc1NeuAc2 (Nr. 64). Complex fuco-
sylated tri- and tetra-antennary glycans presenting terminal galactose residues were also
up-regulated, like HexNAc6Hex6Fuc1 (Nr. 57) and HexNAc6Hex7Fuc2 (Nr. 67).
3.3. Correlation between Relative Levels of N-Glycans in Serum and Tissue of CRC Patients
Eight N-glycan ions presented significantly altered area ratios in both the serum
and tissue of colon cancer patients in relation to controls, all of them detected in LC-
MS/MS analyses of their respective biological materials. None of these were consistently
increased or decreased in tissue and serum. For example, while the oligomannosidic glycan
HexNAc2Hex7 (Nr. 17) was increased in the serum of cancer patients, it was decreased
in tissue. Other N-glycans, like HexNAc5Hex4 (Nr. 22), HexNAc4Hex4NeuAc1 (Nr. 26),
and HexNAc5Hex9 (Nr. 33), while significantly decreased in serum, were increased in
the CRC tissue samples of the same patients. Quantitative correlations between altered
glycans in tissue and their corresponding levels in serum were sought, and not a single
composition showed positive or negative correlation. These analyses jointly illustrate the
complex relationship between N-glycan compositions in tumoral tissue and in the serum
of CRC patients.
4. Discussion
The present work reports the application of a mass spectrometry-based quantitative
methodology for the evaluation of altered N-glycans in the blood serum and cancerous
tissue of CRC patients. By quantifying N-glycans in healthy individuals in relation to a
control pool, it is possible to estimate the variance for each glycan composition found in
the normal population and therefore quantify putative alterations in the serum of CRC
patients. Similar methodology was applied to identify diagnostically relevant N-glycans
present in the plasma of Type II Congenital Disorder of Glycosylation patients, and as
result, it was observed significant alterations even in glycans of low abundance [30].
Several N-glycans were found to be quantitively altered in the blood serum of CRC
patients in relation to control individuals. Initially, fast MALDI-TOF/MS evaluations iden-
tified one up-regulated molecule, while LC-MS/MS analyses identified 23 down-regulated
and 3 up-regulated N-glycan compositions in CRC patients. This suggests that while
MALDI-TOF/MS might be useful as a preliminary tool to assess the quality of the mate-
rial, ion suppression, lack of mass accuracy, and lower resolution power might limit its
capacity to fully determine significant alterations in serum N-glycans of CRC patients,
in consonance with previous reports [30]. Overall, the predominant alteration identified
in LC-MS/MS analyses of the serum of CRC patients was down-regulation of N-glycans
from a large variety of structural families. These include mannose-rich structures, such
as HexNAc2Hex8 (Nr 25), hybrid-type structures, such as HexNAc3Hex5Fuc1NeuAc1
(Nr. 31) and several complex-type structures. Among the latter, down-regulation was
found for hypogalactosilated and hyposilialated N-glycans, such as HexNAc5Hex4 (Nr. 22)
and HexNAc4Hex5Fuc1NeuAc1 (Nr. 44), as well as highly branched structures, such
as HexNAc6Hex6 (Nr. 51) and HexNAc5Hex6NeuAc1 (Nr. 55). Up-regulations were
more specific, and three N-glycans were found to be significantly increased in CRC: the
high-mannose HexNAc2Hex7 (Nr. 17), the complex-type core-fucosylated bi-antennary
HexNAc4Hex5Fuc1NeuAc2 (Nr. 58), and the highly branched HexNAc6Hex7NeuAc3 (Nr.
Biology 2021, 10, 343 25 of 30
79). Based on previous work, which describe the 24 glycoproteins that contribute most
with the plasma N-glycome, HexNAc2Hex7 (Nr. 17), or Man7 according to the Oxford
nomenclature, is found in both Immunoglobulins E and M [24]. Alterations in the levels of
serum immunoglobulins, mainly IgA, IgG, and IgM, have been consistently reported in
CRC, as well as other cancer types [35]. HexNAc4Hex5Fuc1NeuAc2 (Nr. 58), or FA2G2S2,
is found on eleven different glycoproteins, and serotransferrin, alpha-1-antitrypsin, alpha-
2-macroglobulin, IgA1, and IgGs are the ones presenting highest serum concentrations.
Nonetheless, core-fucosylated compositions, catalyzed by enzyme fucosyltransferase-VIII
(FUT-8), have been associated to N-glycosylation of IgGs since hepatic tissues hardly ex-
press FUT-8 activity [36]. Therefore, the observed increase of core-fucosylated biantennary
di-sialo N-glycans may reflect the systemic response of B cells in producing a special
subtype of N-glycosylated IgG against the extraneous tumor tissue [37,38].
N-glycan HexNAc6Hex7NeuAc3 (Nr. 79), or A4G4S3, is found mostly on Alpha-1-
acid glycoprotein (AGP), an acute phase protein associated with the negative modulation
of the complement system and transport of lipophilic compounds [39,40]. The fact that few
N-glycan structures were found to be augmented in CRC deserves further attention, as it
might result from either microheterogeneity in the fore mentioned plasma glycoproteins or
an augmented expression of novel proteins preferentially decorated with these structures.
The alterations in the serum of CRC patients described herein coincide partially with
the literature. A previous work using HILIC chromatography with fluorescence detection
reported a general decrease in bi-antennary core fucosylated structures containing mono
or di-galactosylated moieties involving at most one sialic acid, while a general increase
was observed in glycans from highly branched structures (>3 GlcNAc antennae), rich in
galactose (>3 galactose) and in sialic acid (>3 sialic acids) [27]. In our study, multiple
mono and di-galactosylated structures were indeed decreased, however, the only over-
abundant high-branched structure was HexNAc6Hex7NeuAc3 (Nr. 79). In another study,
in which a PLS-DA model was applied to MALDI-TOF/MS mass spectra of the total
serum N-glycome of controls vs. cases, several N-glycans were found to be differential
in CRC patients, some down- and others up-regulated. Although some alterations agree
with our results, glycan H5N4F1L2, composition HexNAc4Hex5Fuc1NeuAc2 (Nr. 58
in Table 2), was downregulated in this study, contrasting with our findings [41]. This
indicates that the methodology used for data acquisition is a sensitive feature in the
measurement of quantitative alterations in N-glycans of CRC patients, which might be
difficult inter-study comparisons. A summary of our findings compared to the actual
literature on N-glycosylation in serum of CRC patients were compiled in Table S3, provided
in Supplementary Material S5.
Therefore, one feature worthy of evaluation is whether the alterations described herein
can, collectively, be used to discriminate CRC patients from controls in an unbiased larger
sample population.
In the present work, a hierarchical clustering algorithm was applied to the -CH3/-CD3
ratios calculated from LC-MS/MS experiments for the 53 N-glycans quantified in the
blood serum of CRC patients and controls. This is an unsupervised multivariate statistical
method and no information regarding group memberships were provided a priori [42].
Following the clustering of data, approximately eighty-five (85%) of the CRC patients
were grouped in a single cluster, while nearly ninety-one (91%) of the control individuals
were grouped in the alternative cluster. This suggests that the present methodology holds
potential in the diagnosis of CRC patients and that more sophisticated statistical models
might result in even better discrimination. However, it is our understanding that sample
size is a limitation in our study and that it should be significantly increased prior to the
development of more sophisticated models.
It has been suggested that the glycans encountered in human serum are pooled from
all cells in the body, and that these might be altered by pathologies such as cancer [13,17]. N-
glycans in CRC and normal colonic tissues from the same patient were evaluated and their
putative correlations with serum N-glycans were explored. Heterogeneity was a hallmark
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in our findings, indicating that the tumoral micro-environment may vary significantly in
N-glycan content among individuals. This may be attributed to the very heterogeneity
observed in our samples, comprised by stage II and III patients with a variable RAS/RAF
mutational profile, not rarely found in sporadic CRC. In fact, stage II and III make up to 70%
of all CRC cases, whilst mutation in RAS/RAF oncogenes may respond to 40% of CRC as
well [43,44]. Albeit highly heterogenous, not a single composition was found consistently
over- or under-expressed when tumor tissue samples were stratified by primary CRC
location, i.e., right- or left-sided, stage, or mutational status (data not shown). These
findings are in line with the Holm et al. study, in which no difference was found in non-
acidic N-glycans by stage or primary location, even though a N-glycan signature in tumor
stroma has been attributed to stage II CRC samples [19,21].
Nevertheless, our analysis focused in uncovering those glycans that were consistently
altered in CRC patients, and the main findings concern an overall increase in oligomanno-
sidic, bi-antennary mono-galactosylated, and highly branched structures, some of them
presenting core fucosylation. Again, these results overlap only partially with the literature,
as individual structures previously found to be up- or down-regulated in CRC tissue were
not coincident [15,19]. Oligomannosidic and mannose-rich N-glycans are thought to be
abundant in cancerous tissues due to reduced expression of the enzyme MGAT1 [15,45],
responsible for the transformation of high-mannose to hybrid type glycans, while fuco-
sylated structures, mostly core-fucosylated, are thought to arise from an increase in the
expression of the enzyme FUT8 [18,36]. This glycosyltransferase catalyzes the addition
of the α1-6-linked fucose to the core GlcNAc and has been consistently associated with
several types of cancer and to poor prognosis in CRC [18].
Similarly, increase of branched structures has been associated with malignant trans-
formation in many tumors, as in CRC [46]. It is believed that in tumor cells, Ras oncogene
mutation leads to overexpression of MGAT-5, the glycosyltransferase responsible for
adding a β-1,6-N-acetylglucosamine to the core of N-glycans [47]. In turn, branching
compositions on cell surface promotes invasion and decrease cell-cell adhesion mediated
by E-cadherin, both factors associated with worse prognosis in CRC [48].
Bi-antennary mono-galactosylated and mono-galactosylated caped with one sialic
acid compositions were overrepresented in tumor samples. Curiously, these forms are not
usually found increased in CRC [19]. On the contrary, MS-based studies have shown a
decrease rather than increase of bi-antennary compositions, mostly bisected forms [15,16].
Similar with observed in serum, bi-antennae N-glycans are commonly attached to IgG.
Therefore, in tumor tissues, predominance of the aforementioned special type of complex
bi-antennary compositions may indicated a shift of micro-heterogeneity in glycosylation
sites of immunoglobulins G, in favor to a pro-inflammatory subgroup of glycoforms, more
effective in the host response to tumor tissue. A summary of our findings compared to the
actual literature on N-glycosylation in CRC tissue were compiled in Table S4, provided in
Supplementary Material S5.
However, the N-glycans profile of tumor samples hardly mirrored the N-glycans
found in serum samples of CRC patients. The lack of agreement between qualitative
N-glycans profiles is not surprising, as these profiles might arise from distinct sets of
proteins, as previously suggested for ovarian and colorectal cancer [11,49]. In this setting,
serum glycosylation is likely to reflect the N-glycosylation of acute phase response, like in
IgG and α1-acid glycoprotein, rather than glycan composition shed by tumor tissues into
blood [50,51].
Our study focused mainly on compositional nature of glycans. Relative quantification
by MS analysis, of released and labeled N-glycan compositions from biologic samples poses,
in itself, a real challenge in microanalytic research, since biomarker discovery relies on highly
reproductible methods [10,31,34]. Albeit the number of compositions found in our MALDI-
TOF/MS analysis is in line with previous MALDI-TOF/MS-based studies [15,41,52], lack
of agreement between MALDI-TOF/MS and LC-MS/MS measurements is noteworthy. In
contrast to LC-MS/MS analysis, MALDI-TOF/MS analysis yielded only three compositions
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capable of discriminating CRC patients from healthy controls, in both serum and tissue
samples. In our understanding, ion signal suppression is responsible for this discrepancy. In
this sense, we observed that some compositions may have not reached statistical significance
merely due to its low concentration in serum or in tissue samples, the ones more likely to suffer
highest influence from ion signal suppression. Thus, our preliminary set of compositions
relied on MALDI ionization acquisitions whilst our quantitation of structures were restricted
to LC-MS/MS analysis.
Moreover, most of the current knowledge of the N-glycan profile in cancer has been based
on quantification methods by LC-MS technology, such as adopted in this study, with characteri-
zation of N-glycan in a compositional level by accurate mass profiling [10,14–17,19–21,30,31,41].
Notwithstanding, we are aware that in-depth analysis of linkage positions and retention times
of isomers or differential anomeric forms in LC/MS acquisitions, may add new insights on
glycosylation as a source of biomarkers in cancer, what will surely deserve close attention in
further studies.
5. Conclusions
In conclusion, our study revealed a global decrease of galactosylated compositions
present in serum of CRC patients by LC-MS technology. Conversely, three compositions
were upregulated in serum pointing to a subset of structures highly discriminative between
cases from healthy controls. Moreover, our results suggest this panel holds potential
in clinical setting with applications in large scale by automated MS analysis. Albeit
heterogeneous, a commonality of high mannose and branched compositions could be
identified upregulated in tumor tissues. However, some new compositions found an
increase in tumor, as oligomannosidic and bi-antennary mono-galactosylated glycans, have
hardly been described in CRC, what will surely deserve closer attention in further studies.
Curiously, no single N-glycan increase in tissues was found upregulated in serum, which
poses the question where serum compositions in CRC patients are from.
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